PRECISION BIOSCIENCES INC DTIL

About PRECISION BIOSCIENCES INC (DTIL): stock profile, AI score and financials

PRECISION BIOSCIENCES INC (DTIL) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores DTIL at 4.4/100 on a composite quality score built from its SEC filings, placing it at rank #2,922 of 2,925 stocks — the bottom half of the AI-ranked universe. Areas of concern include profitability (0.1) and free cash flow (0.1), which score below median versus the broader universe. Shareholder dilution risk is elevated at 6.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), PRECISION BIOSCIENCES INC reports net income of $-32.7M, free cash flow of $-13.4M. Top institutional holders of DTIL by reported 13-F value include abrdn plc, Bleichroeder, Octagon Capital Advisors, based on the most recent SEC filings. DTIL trades on the Nasdaq exchange and files with the SEC under CIK 1357874. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate DTIL daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for PRECISION BIOSCIENCES INC directly from SEC EDGAR.

Financials through the period ended Jun 30, 2026SEC EDGAR: CIK 1357874 →